A5009233940- Hepatitis C virus research
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Musicology and Musical Analysis
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis B Virus Studies
- Diverse Musicological Studies
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Herpesvirus Infections and Treatments
- Bacterial Infections and Vaccines
- Chronic Lymphocytic Leukemia Research
- Music and Audio Processing
- Musculoskeletal Disorders and Rehabilitation
- Hepatitis Viruses Studies and Epidemiology
- Vaccine Coverage and Hesitancy
- Drug-Induced Hepatotoxicity and Protection
- Diabetes Treatment and Management
- Virology and Viral Diseases
- Influenza Virus Research Studies
- EEG and Brain-Computer Interfaces
- Poxvirus research and outbreaks
- HIV-related health complications and treatments
Merck & Co., Inc., Rahway, NJ, USA (United States)
2016-2025
Cellular Biomedicine Group (United States)
2018
China Medical University
2016
Tel Aviv Sourasky Medical Center
2016
Akershus University Hospital
2016
Montefiore Medical Center
2016
Vancouver Infectious Diseases Centre
2016
Columbia University
2013
Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID).To evaluate elbasvir-grazoprevir treating HCV PWID.Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688).Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, United Kingdom, and States.301 treatment-naive patients with chronic genotype 1, 4, or 6 were at least 80% adherent to visits for opioid agonist therapy (OAT).The immediate-treatment...
Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCETM, Merck Sharp & Dohme Corp., a subsidiary Co., Inc., Kenilworth, NJ, USA) is 15-valent PCV containing 13 in licensed PCV13 and 2 additional (22F, 33F) which significantly contribute burden. This phase 3 trial compared safety, tolerability, immunogenicity adults ≥50 years age. Adults...
Background: Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of clinical lots V114 (investigational 15-valent pneumococcal vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F, 33F*) to 13-valent conjugate vaccine (PCV13) in healthy infants (*serotypes unique V114). Methods: Healthy 6–12 weeks old were randomized receive 4-dose regimen Lot or PCV13 at 2, 6 12–15...
Pneumococcal diseases (PD) cause considerable morbidity and mortality in adults. V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed to protect adults from serotypes responsible for the majority of residual PD. This phase 3 study evaluated safety, tolerability, immunogenicity vaccine-experienced ≥50 years.
Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause mortality in people HIV. We aimed to verify whether affected overall survival (OS) HCC, independent treatment and geographic origin.We designed an international multicohort study HCC accrued from four continents who did not receive any anticancer treatment. estimated effect on patients' OS while accounting for common prognostic factors demographic...
Abstract Background Adults with certain underlying chronic medical conditions are at increased risk of pneumococcal disease (PD). V116 is an investigational, 21-valent, adult-specific conjugate vaccine (PCV) containing the most prevalent serotypes (STs) associated PD in adults from regions established pediatric vaccination programs. The Phase 3 STRIDE-8 study (NCT05696080) evaluated safety and tolerability 18–64 years age PD. Immunogenicity was compared sequential administration 15-valent...
Background: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. Objective: To evaluate rate HCV for 3 years receiving opioid agonist therapy (OAT). Design: A 3-year, long-term, extension study persons enrolled in CO-STAR (Hepatitis Patients on Opioid Substitution Therapy Antiviral Response) (ClinicalTrials.gov: NCT02105688). Setting: 55 clinical trial sites 13 countries. Patients: Aged 18 and older with chronic...
Background: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) designed for adults. It contains the most prevalent serotypes associated with invasive disease (IPD) in adults regions established pediatric vaccination programs. This Phase 3 study compared safety, tolerability, and immunogenicity of 23-valent polysaccharide (PPSV23) ≥50 years age. Methods: In this randomized, active comparator-controlled, parallel-group, multisite, double-blind study, participants were randomized 1:1 to...
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult disease after introduction pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in invasive (IPD). This Phase I study assessed safety, tolerability, immunogenicity Japanese adults. Participants ≥20 years age were randomized receive a single dose or 23-valent polysaccharide (PPSV23) at day 1. Outcomes solicited injection-site systemic...
Hepatocellular carcinoma (HCC) is a leading cause of liver-related mortality in people living with HIV, where co-infection hepatotropic viruses accelerates the course chronic liver disease.To evaluate whether albumin-bilirubin (ALBI) grade, more accurate marker dysfunction HCC, might identify patients progressive context HIV/hepatitis co-infection.Using uni- and multi-variable analyses, we studied grade as predictor overall survival (OS) large, multi-center cohort HIV-associated HCC...
Abstract Ruzasvir ( MK ‐8408, an NS 5A inhibitor) and uprifosbuvir ‐3682, a nonstructural protein 5B nucleotide are highly potent direct‐acting antiviral agents for the treatment of hepatitis C virus HCV ) infection. A phase III clinical trial evaluating two‐drug combination ruzasvir 60 mg plus 450 suggested suboptimal efficacy in certain genotypes (C‐ BREEZE 1; NCT 02759315). The aim present study was to evaluate safety with administered at higher dose than that assessed earlier 2:...
INTRODUCTION: Treatment options are limited for people infected with hepatitis C virus (HCV) decompensated liver disease. The C-SALT study assessed elbasvir (EBR) plus grazoprevir (GZR) in individuals HCV genotype 1 infection and Child-Pugh class B (CP-B) cirrhosis. METHODS: In this 12-week, phase 2, nonrandomized, open-label (NCT02115321; Protocol MK-5172-059), participants CP-B cirrhosis received EBR 50 mg GZR once daily, a control group of noncirrhotic 100 daily. primary endpoint was...
Cuccurullo S, Brown D, Petagna AM, Platt H, Strax TE: Musculoskeletal injection skills competency in physical medicine and rehabilitation residents: A method for development assessment. Am J Phys Med Rehabil 2004;83:479–485. An educational module was developed attempt to satisfy two main objectives: develop implement a methodology instruction of generally encountered techniques the practice an objective assessment format measure attainment these skills. Guidelines this were consideration...